The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
More to come in due course by the sounds of it.
Hardman reckons the share have "substantial valuation potential".
---
"Our next note will provide further scientific background, full financial analysis, and a better understanding of STX’s
substantial valuation potential."
Yes, nice coverage.
----
"There are multiple potential inflection points ahead"
"STX has very limited risk because of the simplicity and low clinical risk of Feraccru, in addition to the fact that it has received regulatory approval in Europe and a decision date for US FDA approval"
"Given the potential news flow, a market capitalisation of just £49m makes STX a very interesting investment proposition."
"Friday .............. it’s been a busy start to the year already. Looking forward to next week, tender clarifications, offtake meetings, visit to site in Islandmagee for meetings, Oil Capital Conference, AGM and finishing off with our board meeting. #INFA"
https://twitter.com/JohnWoo64494325/status/1088860084124438528
Proactive Investors presentation from yesterday evening:
https://www.shieldtherapeutics.com/wp-content/uploads/2019/01/STX-investor-presentation-January-2019.pdf
Another positive here is significant CEO skin in the game. His latest purchase was for £30k worth in Sep 2018. That took him to 10,163,496 shares.
https://investegate.co.uk/shield-therapeutics--stx-/rns/director-pdmr-shareholding/201809241306357256B/
At the current 41p bid, that means he's got £4.1 million invested here.
So he is very heavily incentivised indeed to drive the share price higher. Great to have management fortunes so closely aligned to those of shareholders.
Nice position size there. 60 million shares. £760k or so worth.
Certainly confident.
Liberum Capital has an 80p target on the shares. "With enough cash to fund the business into 2020 and two potentially major share price catalysts in the next six months, Liberum reiterated its 'buy' rating"
"Peel Hunt said its target price of 70p implies more than 100% upside “and includes nothing for the US market”, which Peel Hunt estimates could be worth an additional 85p per share on a partnered basis.
“If FDA approval is received this year, the US market offers further very strong near-term expansion potential for Feraccru,” the broker said."
http://goo.gl/yzH6YC
https://audioboom.com/posts/7153214-united-oil-gas-shield-therapeutics-and-chris-bailey
"There was a substantial upfront and some near-term milestones which we haven't yet made public at the request of LG, but we will do later in the year." - 1:16
"We said at the time that Tufts deal was transformational and I'm very confident that that is the case." - 3:38
"The momentum is genuinely there. It's going to be a really exciting year for Avacta." - 7:40
Always good to see management align their interests with shareholders.
And it's very much the case here with the Chairman clearly very confident indeed that the company is going places investing heavily last month at the equivalent of 9p.
https://investegate.co.uk/mkango-resources-ltd--mka-/rns/mkango-announces-director-dealing/201812050700044297J
"It also shows from our Chairmans perpsective great confidence in the company. So he's acquired warrants over about 3.3 million shares which would equate to around 3% of the company."
https://www.youtube.com/watch?v=QDA3KJJKEVA (from 4:29)
The First Equity note is well worth reading and highlights the significant potential upside in MKA from the current price.
"Our investment thesis for Mkango, which we set out in more detail below, is simple: it is the most attractively valued pre-production stage, ex-China REE project on all public markets."
"A crucial element of the agreement between Mkango and Talaxis is the option clause. This stipulates that upon completion of the BFS, Talaxis has the option of increasing its stake in Songwe Hill from 49% to 75% by securing all project finance (estimated at $216m in the PFS – or £168m at current exchange rates). Were Talaxis to fund this capex entirely in the form of equity, that would take its total investment in Songwe Hill to £180m. Based on this transaction, that would value Songwe Hill at £240m – and Mkango’s 25% remaining equity stake at £60m, or 53.1p per share using the current issued share capital of 112.9m."
"At its current share price of 9.95p, Mkango is valued at only £11.2m. We consider this to be brutally undervalued, in light of the size, quality and strategic importance (both from a commercial and a political sense) of Songwe Hill, and of the valuation attributed to it by the Talaxis deal."
https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf
"£5m of this was received in January 2018, which gave Talaxis an initial 20% stake. The remaining £7m is due to be paid in Q1 2019."
https://gallery.mailchimp.com/d266f47cec87da1170bcd0f35/files/5bf0e4f5-88e8-428a-841e-63d25ffd8bf2/Top_10_Micro_Cap_Picks_Part_I.01.pdf
https://cube.investments/infrastrata-infa-gas-powering-my-portfolio/
https://www.finncap.com/news-events/finncap-research-company-notes-21-january-2019
Avacta Group trading in line in "year of very significant progress"
http://goo.gl/Rd3qmp
From the other BB...
---
finnCap today reiterate 120p target...
"Avacta (AVCT): Corp
AGM business update – preclinical progress on 2 fronts
The company has confirmed that H1 FY 2019 is trading in line with market forecasts, and updates relating to its lead bispecific PD-L1/LAG3 Affimer, TMAC Affimer drug conjugate platform and its collaboration with Moderna are encouraging, providing further evidence of the incremental value being created in its Affimer-driven technology platforms.
Management is confident that there will be multiple reagent licensing deals in 2019, given the pipeline of late-stage interest from potential parties. Equally, we would hope/expect further therapeutic licences during 2019, given the preclinical progress that is being made, and building on the LG Chem development deal in December, which has a biodollar value of up to $300m plus royalties.
We reiterate a target price of 120p."